| 【英語タイトル】Global Cardiovascular Clinical Trials Market Size study & Forecast, by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design (Interventional, Observational, Expanded Access), by Indication (Acute Coronary Syndrome, Coronary Artery Disease, Ischemic Heart Disease, Pulmonary Arterial Hypertension, Stroke/Cerebrovascular Disease, Cardiac Arrhythmias, Heart Failure, Others) and Regional Analysis, 2022-2029
|
 | ・商品コード：BZW23MA156
・発行会社（調査会社）：Bizwit Research & Consulting
・発行日：2023年4月17日
・ページ数：約200
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、
・産業分野：医療
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
❖ レポートの概要 ❖
Bizwit Research社発行の本調査レポートによると、2021年にXX億ドルであった世界の心臓血管における臨床試験市場規模が、予測期間中（2022年-2029年）にXX%以上成長すると予想されます。本レポートは、心臓血管における臨床試験の世界市場を調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、フェーズ別（フェーズI、フェーズII、フェーズIII、フェーズIV）分析、研究デザイン別（介入研究、観察研究、拡大参加試験）分析、疾患別（急性冠症候群、冠動脈疾患、虚血性心疾患、肺動脈性肺高血圧症、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、その他）分析、競争分析、調査プロセスなどの内容を掲載しています。なお、参入企業情報として、Medpace、IQVIA Inc、ICON Plc、Charles River Laboratories Inc.、Wuxi App Tec、Laboratory Corporation of America Holdings、PAREXEL International Corporation、Eli Lilly and Company、Pharmaceutical Product Development, LLC、Pfizer Inc.などが含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界の心臓血管における臨床試験市場規模：フェーズ別
- フェーズIの市場規模
- フェーズIIの市場規模
- フェーズIIIの市場規模
- フェーズIVの市場規模
・世界の心臓血管における臨床試験市場規模：研究デザイン別
- 介入研究の市場規模
- 観察研究の市場規模
- 拡大参加試験の市場規模
・世界の心臓血管における臨床試験市場規模：疾患別
- 急性冠症候群の市場規模
- 冠動脈疾患の市場規模
- 虚血性心疾患の市場規模
- 肺動脈性肺高血圧症の市場規模
- その他疾患の市場規模
・世界の心臓血管における臨床試験市場規模：地域別
- 北米の心臓血管における臨床試験市場規模
アメリカの心臓血管における臨床試験市場規模
カナダのの心臓血管における臨床試験市場規模
…
- ヨーロッパの心臓血管における臨床試験市場規模
イギリスの心臓血管における臨床試験市場規模
ドイツの心臓血管における臨床試験市場規模
フランスの心臓血管における臨床試験市場規模
…
- アジア太平洋の心臓血管における臨床試験市場規模
中国の心臓血管における臨床試験市場規模
インドの心臓血管における臨床試験市場規模
日本の心臓血管における臨床試験市場規模
…
- 中南米の心臓血管における臨床試験市場規模
ブラジルの心臓血管における臨床試験市場規模
メキシコの心臓血管における臨床試験市場規模
…
- その他地域の心臓血管における臨床試験市場規模
・競争分析
・調査プロセス |
Global Cardiovascular Clinical Trials Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Clinical trials are medical research studies designed to assess novel approaches to disease prevention, diagnosis, and treatment. Clinical trials are used by researchers to evaluate the safety and efficacy of new treatments for patients. Clinical trials in the field of cardiovascular medicine particularly examine novel therapies for heart problems. Throughout the course of the projection period, it is predicted that the global market for cardiovascular clinical trials would expand significantly. The rising prevalence of cardiovascular disorders such as stroke, heart failure, and coronary artery diseases is one of the main reasons propelling the market’s expansion. Also, growing government and industry investment as well as increased consumer demand for phase III trial cost reductions are both driving the market’s expansion. Moreover, the rising high government support, growing initiatives by the key market players is creating a lucrative growth opportunity for the market over the forecast period 2022-2029.
For instance, cardiovascular disorders continue to be the major cause of death worldwide, according to a WHO report from 2021. Estimates indicate that 17.9 million individuals died from CVDs in 2019, with the bulk of these deaths occurring in low- and middle-income nations. Phase III clinical studies typically cost USD 22.8 million or more. Moreover, Phase III calls for a larger patient population and frequently a longer course of treatment. As of January 2023, there was about 830 cardiovascular phase III clinical studies listed on clinicaltrials.gov, according to clinicaltrials.gov. However, the high cost of Cardiovascular Clinical Trials stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Cardiovascular Clinical Trials Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Due to factors such as increased R&D spending and rising cardiovascular disease prevalence, North America is predicted to have the largest market share over the projection period. For instance, from 2001 to 2025, many registered clinical trials and research dates originated in the United States. Clinicaltrials.gov estimates that 4,058 cardiovascular clinical trials will be conducted in the United States in 2022. Along with this, Asia-Pacific is growing with the fastest CARG over the forecast period due to the rising number of geriatric population and growing prevalence of cardiovascular diseases.
Major market player included in this report are:
Medpace
IQVIA Inc
ICON Plc
Charles River Laboratories Inc.
Wuxi App Tec
Laboratory Corporation of America Holdings
PAREXEL International Corporation
Eli Lilly and Company
Pharmaceutical Product Development, LLC
Pfizer Inc.
Recent Developments in the Market:
In Aug 2021, The U.S. Food and Drug Administration (FDA) approved an expanded label for Eli Lilly and Company’s rapid-acting Cardiovascular Clinical Trials, Lyumjev (Cardiovascular Clinical Trials lispro-AABC injection) 100 units/mL indicated to improve glycemic control in adults with Indication 1 and Indication 2 diabetes, to include administration via continuous subcutaneous Cardiovascular Clinical Trials infusion (CSII) with a Cardiovascular Clinical Trials pump.
In July 2021, Semglee, a first-of-its-kind Cardiovascular Clinical Trials Phase made by India’s Biocon, gets United States approval. Semglee, manufactured by Biocon Biologics, a Bengaluru-based pharmaceutical company, is both interchangeable with and biosimilar to Lantus, a long-acting Cardiovascular Clinical Trials Phase already approved in the United States.
Global Cardiovascular Clinical Trials Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Phase, Study Design, Indication, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Phase offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Phase:
Phase I
Phase II
Phase III
Phase IV
By Study Design:
Interventional
Observational
Expanded Access
By Indication:
Acute Coronary Syndrome
Coronary Artery Disease
Ischemic Heart Disease
Pulmonary Arterial Hypertension
Stroke/Cerebrovascular Disease
Cardiac Arrhythmias
Heart Failure
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Cardiovascular Clinical Trials Market, by Region, 2019-2029 (USD Billion)
1.2.2. Cardiovascular Clinical Trials Market, by Phase, 2019-2029 (USD Billion)
1.2.3. Cardiovascular Clinical Trials Market, by Study Design, 2019-2029 (USD Billion)
1.2.4. Cardiovascular Clinical Trials Market, by Indication, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Cardiovascular Clinical Trials Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Cardiovascular Clinical Trials Market Dynamics
3.1. Cardiovascular Clinical Trials Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of cardiovascular disorders
3.1.1.2. Growing Geriatric Population
3.1.2. Market Challenges
3.1.2.1. High Cost of Cardiovascular Clinical Trials
3.1.3. Market Opportunities
3.1.3.1. High government support
3.1.3.2. Rising inititiaves by the key market players
Chapter 4. Global Cardiovascular Clinical Trials Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Cardiovascular Clinical Trials Market, by Phase
6.1. Market Snapshot
6.2. Global Cardiovascular Clinical Trials Market by Phase, Performance – Potential Analysis
6.3. Global Cardiovascular Clinical Trials Market Estimates & Forecasts by Phase 2019-2029 (USD Billion)
6.4. Cardiovascular Clinical Trials Market, Sub Segment Analysis
6.4.1. Phase I
6.4.2. Phase II
6.4.3. Phase III
6.4.4. Phase IV
Chapter 7. Global Cardiovascular Clinical Trials Market, by Study Design
7.1. Market Snapshot
7.2. Global Cardiovascular Clinical Trials Market by Study Design, Performance – Potential Analysis
7.3. Global Cardiovascular Clinical Trials Market Estimates & Forecasts by Study Design 2019-2029 (USD Billion)
7.4. Cardiovascular Clinical Trials Market, Sub Segment Analysis
7.4.1. Interventional
7.4.2. Observational
7.4.3. Expanded Access
Chapter 8. Global Cardiovascular Clinical Trials Market, by Indication
8.1. Market Snapshot
8.2. Global Cardiovascular Clinical Trials Market by Indication, Performance – Potential Analysis
8.3. Global Cardiovascular Clinical Trials Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
8.4. Cardiovascular Clinical Trials Market, Sub Segment Analysis
8.4.1. Acute Coronary Syndrome
8.4.2. Coronary Artery Disease
8.4.3. Ischemic Heart Disease
8.4.4. Pulmonary Arterial Hypertension
8.4.5. Stroke/Cerebrovascular Disease
8.4.6. Cardiac Arrhythmias
8.4.7. Heart Failure
8.4.8. Others
Chapter 9. Global Cardiovascular Clinical Trials Market, Regional Analysis
9.1. Cardiovascular Clinical Trials Market, Regional Market Snapshot
9.2. North America Cardiovascular Clinical Trials Market
9.2.1. U.S. Cardiovascular Clinical Trials Market
9.2.1.1. Phase breakdown estimates & forecasts, 2019-2029
9.2.1.2. Study Design breakdown estimates & forecasts, 2019-2029
9.2.1.3. Indication breakdown estimates & forecasts, 2019-2029
9.2.2. Canada Cardiovascular Clinical Trials Market
9.3. Europe Cardiovascular Clinical Trials Market Snapshot
9.3.1. U.K. Cardiovascular Clinical Trials Market
9.3.2. Germany Cardiovascular Clinical Trials Market
9.3.3. France Cardiovascular Clinical Trials Market
9.3.4. Spain Cardiovascular Clinical Trials Market
9.3.5. Italy Cardiovascular Clinical Trials Market
9.3.6. Rest of Europe Cardiovascular Clinical Trials Market
9.4. Asia-Pacific Cardiovascular Clinical Trials Market Snapshot
9.4.1. China Cardiovascular Clinical Trials Market
9.4.2. India Cardiovascular Clinical Trials Market
9.4.3. Japan Cardiovascular Clinical Trials Market
9.4.4. Australia Cardiovascular Clinical Trials Market
9.4.5. South Korea Cardiovascular Clinical Trials Market
9.4.6. Rest of Asia Pacific Cardiovascular Clinical Trials Market
9.5. Latin America Cardiovascular Clinical Trials Market Snapshot
9.5.1. Brazil Cardiovascular Clinical Trials Market
9.5.2. Mexico Cardiovascular Clinical Trials Market
9.6. Rest of The World Cardiovascular Clinical Trials Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Medpace
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. IQVIA Inc.
10.2.3. ICON Plc
10.2.4. Charles River Laboratories Inc.
10.2.5. Wuxi App Tec
10.2.6. Laboratory Corporation of America Holdings
10.2.7. PAREXEL International Corporation
10.2.8. Eli Lilly and Company
10.2.9. Pharmaceutical Product Development, LLC
10.2.10. Pfizer Inc.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
11.3. Research Assumption
